Checkmate Pharmaceuticals is a company.
Checkmate Pharmaceuticals has raised $154.0M across 4 funding rounds.
Key people at Checkmate Pharmaceuticals.
Checkmate Pharmaceuticals has raised $154.0M in total across 4 funding rounds.
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing proprietary immunotherapies to harness the immune system against cancer.[1][2] Its lead product candidate, vidutolimod (CMP-001), is a Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle (VLP) containing CpG-A oligodeoxynucleotide, designed to trigger innate immune responses in tumors when combined with therapies like nivolumab (OPDIVO).[1] The company targets anti-PD-1 refractory and first-line melanoma patients through ongoing Phase II and Phase II/III trials, addressing unmet needs in immunotherapy-resistant cancers with a protected delivery mechanism that prevents oligonucleotide degradation.[1][3] With 31 employees, Checkmate focuses on bio-therapeutic drugs in biotechnology and medical research.[1]
Checkmate Pharmaceuticals emerged as a clinical-stage biotech firm specializing in immune-oncology, with key leadership including CTOs Chris French (since 2016) and James Wooldridge (since 2019), alongside CFO Robert Landry (since 2022).[1] The company's idea stemmed from advancing TLR9 agonist technology into a novel VLP format for intratumoral delivery, building on CpG oligonucleotides to enhance immune activation against solid tumors.[1][3] Early traction involved initiating clinical trials, such as a Phase II study with nivolumab in refractory melanoma and a randomized Phase II/III trial in first-line melanoma, marking pivotal moments in validating vidutolimod's potential.[1]
Checkmate rides the immuno-oncology wave, particularly next-generation agonists enhancing checkpoint inhibitors amid rising resistance in PD-1 therapies.[1][3] Timing aligns with market forces favoring combination regimens, as monotherapy limitations drive demand for intratumoral agents like TLR9 agonists to reprogram cold tumors.[1] It influences the ecosystem by advancing VLP platforms, potentially expanding to colorectal and other solid tumors, and contributing to biotech innovation in personalized cancer immunotherapies.[3]
Checkmate's trajectory hinges on readout from its Phase II/III melanoma trials, with positive data potentially accelerating vidutolimod toward approval and partnerships.[1][3] Trends like AI-driven trial design and bispecific combos will shape progress, amplifying its VLP tech in a $100B+ immuno-oncology market. Influence may evolve through acquisitions or expansions into adjuvant settings, solidifying its role in turning refractory cancers into curable ones—echoing its core mission to unlock immune potential against tumors.[1][2]
Checkmate Pharmaceuticals has raised $154.0M in total across 4 funding rounds.
Checkmate Pharmaceuticals's investors include Andreessen Horowitz, Cofounders Capital, F-Prime Capital Partners, Locus Ventures, Carol Gallagher, NextView Ventures, Omega Funds, Runway Growth Capital, SV Health Investors, The Column Group, The House Fund, venBio.
Key people at Checkmate Pharmaceuticals.
Checkmate Pharmaceuticals has raised $154.0M across 4 funding rounds. Most recently, it raised $85.0M Series C in June 2020.
